(Q43001794)

12 November 2017

Hepatitis C treatment among racial and ethnic groups in the IDEAL trial (English)

1 reference

12 November 2017

8

M S Sulkowski

1 reference

12 November 2017

A J Muir

1

1 reference

12 November 2017

K-Q Hu

2

1 reference

12 November 2017

S C Gordon

3

1 reference

12 November 2017

K Koury

4

1 reference

12 November 2017

N Boparai

5

1 reference

12 November 2017

S Noviello

6

1 reference

12 November 2017

J K Albrecht

7

1 reference

12 November 2017

J McCone

9

1 reference

12 November 2017

25 November 2010

1 reference

Journal of Viral Hepatitis

12 November 2017

1 reference

12 November 2017

18

1 reference

12 November 2017

e134-43

1 reference

12 November 2017

4

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

12 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Differences in treatment outcome for hepatitis C among ethnic groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Race, insulin resistance and hepatic steatosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Peginterferon Pharmacokinetics in African American and Caucasian American Patients With Hepatitis C Virus Genotype 1 Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01402.X

10.1111/J.1365-2893.2010.01402.X

21 January 2018

Identifiers

DOI

1 reference

release_ca6dfitlqfezjoubnw6brlm764

12 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ca6dfitlqfezjoubnw6brlm764

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference